{{Infobox Perusahaan|name=Eisai Co., Ltd.|logo=|type=[[publicperusahaan companypublik|PublicPublik]] [[Kabushiki kaisha|KK]]|traded_as={{TYO|4523}}<br>[[Topix|TOPIX Large 70 Component]]<br>[[Topix|TOPIX 100 Component]]<br>[[Nikkei 225|Nikkei 225 Component]]|industry=[[PharmaceuticalPerusahaan companyfarmasi|PharmaceuticalsFarmasi]]|foundation=({{Start date and age|1941|12|06}})|founder=Toyoji Naito|hq_location=4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, JapanJepang|location=4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, JapanJepang|key_people=Haruo Naito<br><small>([[President (corporate title)|President]] and [[CEO]])</small>|products={{unbulleted list|[[Eribulin|Halaven]]|[[Donepezil|Aricept]]|[[Rabeprazole|Pariet]]|[[Banzel]]|[[Zonisamide#History|Zonegran]]|[[Perampanel|Fycompa]]|[[Eslicarbazepine acetate|Zebinix]]}}|revenue={{increase}} [[US dollar|US$]] 5.82 billionmiliar ([[FiscalTahun yearfiskal|FYTF]] 2013) ([[Japanese yenYen|JPY]] 600.4 billionmiliar) (FYTF 2013)|net_income={{increase}} US$ 320 millionjuta (FYTF 2013) (JPY 33 billionmiliar) (FY 2013)|num_employees=10,419 (consolidatedterkonsolidasi, as31 of March 31,Maret 2014)|homepage={{Official website|http://www.eisai.com/index.html}}|footnotes=<ref>{{cite web |url=http://www.eisai.com/company/profile/index.html |title=Corporate Information |publisher=Eisai Co., Ltd. |accessdate=February 9, 2015}}{{self-published inline|certain=y|date=March 2015}}</ref>}}{{Nihongo|'''Eisai Co., Ltd.'''|エーザイ株式会社|Ēzai Kabushiki-gaisha}} adalah perusahaan farmasi Jepang yang berkantor pusat di [[Tokyo]], Jepang. Memiliki sekitar 10.000 karyawan, 1.500 di antaranya bekerja dalam penelitian. '''Eisai''' terdaftar di [[Bursa efek Tokyo|Bursa Saham Tokyo]] dan merupakan anggota dari [[indeks saham]] [[Topix|Topix 100]] dan [[Nikkei 225]].<ref>{{cite web|url=http://indexes.nikkei.co.jp/en/nkave/index/component?idx=nk225#09|title=Components:Nikkei Stock Average|publisher=[[Nihon Keizai Shimbun]]|accessdate=February 9, 2015}}</ref>
